Article citationsMore>>

Meng, W., Ellsworth, B.A., Nirschl, A.A., McCann, P.J., Patel, M., Girotra, R.N., Wu, G., Sher, P.M., Morrison, E.P., Biller, S.A., Zahler, R., Deshpande, P.P., Pullockaran, A., Hagan, D.L., Morgan, N., Taylor, J.R., Obermeier, M.T., Humpherys, W.G., Khanna, A., Discenza, L., Robertson, J.G., Wang, A., Han, S., Wetterau, J.R., Janovitz, E.B., Flint, O.P., Whaley, J.M. and Washburn, W.N. (2008) Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose co Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry, 51, 1145-1149.
http://dx.doi.org/10.1021/jm701272q

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top